ArticleCancer diagnosis & prognosis

Risk Factor for Rash in Patients Receiving Cytarabine and Idarubicin Induction Therapy for Acute Myeloid Leukemia.

Mayako Uchida et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.